Table 2

Outcomes from randomized phase 3 clinical trials of different treatment regimens in elderly patients with NDMM

RegimenMedian age, yDosingCR rate, %Median PFS, moMedian OS, moDiscontinuation rate, %Nonhematologic grade 3-4 AEs, %
MPT4869M: 0.25 mg/kg on days 1-4 for twelve 6-wk cycles
P: 40 mg/m2 on days 1-4 for twelve 6-wk cycles
T: 400 mg/d for twelve 6-wk cycles
1328524542
MPT49,5072M: 4 mg/m2 on days 1-7 for six 4-wk cycles
P: 40 mg/m2 on days 1-7 for six 4-wk cycles
T: 100 mg/d until relapse
1622453455*
MPT5272M: 0.25 mg/kg on days 1-5 for eight 4-wk cycles
P: 1 mg/kg on days 1-5 for eight 4-wk cycles
T: 200 mg/d for eight 4-wk cycles, followed by 50 mg/d until relapse
2313403650
MPT5378M: 0.2 mg/kg on days 1-4 for twelve 6-wk cycles
P: 2 mg/kg on days 1-4 for twelve 6-wk cycles
T: 100 mg/d for twelve 6-wk cycles
7244442NA
MPT5474M: 0.25 mg/kg on days 1-4 for 6-wk cycles until plateau
P: 100 mg/d on days 1-4 for 6-wk cycles until plateau
T: 400 mg/d until plateau, reduced to 200 mg/d until progression
1315293240
MPT5569M: 9 mg/m2 on days 1-4 for eight 6-wk cycles
P: 60 mg/m2 on days 1-4 for eight 6-wk cycles
T: 100 mg/d for eight 6-wk cycles, followed by100 mg/d until relapse
921§2616NA
VMP47,5671V: 1.3 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 for first four 6-wk cycles; days 1, 8, 15, and 22 for subsequent five 6-wk cycles
M: 9 mg/m2 on days 1-4 for five 6-wk cycles
P: 60 mg/m2 on days 1-4 for five 6-wk cycles
30NANot reached3491*
VMP5771V: 1.3 mg/m2 on days 1, 8, 15, and 22 for nine 5-wk cycles
M: 9 mg/m2 on days 1-4 for nine 5-wk cycles
P: 60 mg/m2 on days 1-4 for nine 5-wk cycles
2423Not reached1733
MPR-R58NAM: 0.18 mg/kg on days 1-4 for nine 4-wk cycles
P: 2 mg/kg on days 1-4 for nine 4-wk cycles
R: 10 mg on days 1-21 for nine 4-wk cycles
R: 10 mg/d until relapse
1631Not reached14NA
Rd5166R: 25 mg on days 1-21
d: 40 mg on days 1, 8, 15, 22 in 4-wk cycles
425Not reached19NA
VMPT5771V: 1.3 mg/m2 on days 1, 8, 15, and 22 for nine 5-wk cycles and on days 1, 15 until relapse
M: 9 mg/m2 on days 1-4 for nine 5-wk cycles
P: 60 mg/m2 on days 1-4 for nine 5-wk cycles
T: 50 mg daily until relapse
38Not reachedNot reached2346
  • CR indicates complete response; PFS, progression-free survival; OS, overall survival; AE, adverse event; MPR-R, melphalan, prednisone, and lenalidomide followed by lenalidomide maintenance; NA, not available; Rd, lenalidomide plus low-dose dexamethasone; VMP, bortezomib, melphalan, and prednisone; and VMPT, bortezomib, melphalan, prednisone, and thalidomide.

  • * Both hematologic and nonhematologic AEs.

  • CR plus very good partial response (CR alone not available).

  • Event-free survival.

  • § Disease-free survival.

  • Includes both patients who received lenalidomide maintenance and those who did not.